<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00692016</url>
  </required_header>
  <id_info>
    <org_study_id>13080</org_study_id>
    <nct_id>NCT00692016</nct_id>
  </id_info>
  <brief_title>Fast &amp; Fed Pharmacokinetic (PK) Study</brief_title>
  <acronym>Keifer</acronym>
  <official_title>An Open Label, Randomized, Two-Way Crossover Study to Determine the Bioavailability of a Single, Oral Dose of an Extended Release Naproxen Sodium Tablet Under Fasting and Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide information on how well an extended release&#xD;
      formulation (a medication that is released and absorbed over a longer period of time than a&#xD;
      regular release formulation of the medication) of naproxen sodium is absorbed into the&#xD;
      bloodstream after eating a high calorie breakfast and also after fasting (not eating for 14&#xD;
      hours).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameters</measure>
    <time_frame>Over 48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the tolerability of the investigational product.</measure>
    <time_frame>Over 48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Bioavailability</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen sodium</intervention_name>
    <description>Administered under fasting condition</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen sodium</intervention_name>
    <description>Administered under fed condition</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, ambulatory, male and female volunteers between 18 to 55 years of age with a&#xD;
             Body Mass Index (BMI) of approximately 18 to 30 kg/m2, and a total body weight &gt; 50 kg&#xD;
             (110 lbs);&#xD;
&#xD;
          -  Results of screening and clinical laboratory tests are within normal range or&#xD;
             considered not clinically significant by the Principal Investigator and the Sponsor;&#xD;
&#xD;
          -  Female subjects of childbearing potential must be using a medically acceptable form of&#xD;
             birth control for at least 1 month prior to screening (3 months on oral&#xD;
             contraceptives), e.g., oral or patch contraceptives, intrauterine device, NuvaRing®,&#xD;
             Depo-Provera®, or double-barrier and have a negative pregnancy test at Screening and&#xD;
             Day 0 of each dosing period. Female subjects of nonchildbearing potential must be&#xD;
             amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity to aspirin (ASA), naproxen sodium, or acetaminophen, and&#xD;
             similar pharmacological agents or components of the products;&#xD;
&#xD;
          -  Females who are pregnant or lactating;&#xD;
&#xD;
          -  Loss of blood in excess of 500 ml within 56 days of the first dose of trial treatment&#xD;
             (e.g., donation, plasmapheresis or injury);&#xD;
&#xD;
          -  History of gastrointestinal bleeding or perforation, related to previous NSAID&#xD;
             therapy. Active, or history of recurrent peptic ulcer/hemorrhage (two or more distinct&#xD;
             episodes of proven ulceration or bleeding);&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases&#xD;
             or malignancies;&#xD;
&#xD;
          -  Positive alcohol or drug test;&#xD;
&#xD;
          -  Have taken any medications (except acceptable forms of birth control) within 10 days&#xD;
             prior to dosing or throughout the study, unless in the opinion of the Investigator and&#xD;
             the Sponsor, the medication will not interfere with the study procedures, data&#xD;
             integrity, or compromise the safety of the subject;&#xD;
&#xD;
          -  Have taken ASA, ASA-containing products, acetaminophen (acetyl-para-amino-phenol or&#xD;
             APAP) or any other NSAID (OTC or prescription) 7 days prior to dosing or during the&#xD;
             treatment period, other than study treatment;&#xD;
&#xD;
          -  Smokers or currently consuming any type of tobacco product(s) including any smoking&#xD;
             cessation nicotine-containing product (e.g., nicotine patch, nicotine gum);&#xD;
&#xD;
          -  Have taken any vitamin or herbal supplement within 7 days prior to dosing or refuse to&#xD;
             refrain from use during the study;&#xD;
&#xD;
          -  Alcoholism or drug abuse within 2 years prior to the Screening Visit;&#xD;
&#xD;
          -  Participation in any other trials involving investigational or marketed products&#xD;
             within 30 days prior to the Screening Visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>June 5, 2008</study_first_submitted>
  <study_first_submitted_qc>June 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <last_update_submitted>May 1, 2013</last_update_submitted>
  <last_update_submitted_qc>May 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2013</last_update_posted>
  <responsible_party>
    <name_title>Therapeutic Area Head</name_title>
    <organization>Bayer Consumer Care Inc.</organization>
  </responsible_party>
  <keyword>Naproxen Sodium</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

